Circulating Tumor Cell-based Molecular Responses Stratify EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Cancer

Key Points

• CTC analysis shows potential as a biomarker for predicting treatment response and prognosis in EGFR-mutant lung cancer.
• Stratification by CTC molecular response is linked to risk adaptation in treatment strategies, enhancing personalized care.
• Prospective studies are warranted to validate CTC findings and assess their clinical utility in decision-making.
• Potential for CTC-guided treatment may enable personalized therapies, though current clinical applications require further validation.